Cargando…
Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976108/ https://www.ncbi.nlm.nih.gov/pubmed/29862052 http://dx.doi.org/10.1136/esmoopen-2018-000377 |
| _version_ | 1783327116011503616 |
|---|---|
| author | Argiles, Guillem |
| author_facet | Argiles, Guillem |
| author_sort | Argiles, Guillem |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5976108 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59761082018-06-01 Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer Argiles, Guillem ESMO Open Podcast BMJ Publishing Group 2018-05-20 /pmc/articles/PMC5976108/ /pubmed/29862052 http://dx.doi.org/10.1136/esmoopen-2018-000377 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | Podcast Argiles, Guillem Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title_full | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title_fullStr | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title_full_unstemmed | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title_short | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| title_sort | initial experience with the bispecific anti-cea anti-cd3 antibody and its expected impact on future treatment for patients with colorectal cancer |
| topic | Podcast |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976108/ https://www.ncbi.nlm.nih.gov/pubmed/29862052 http://dx.doi.org/10.1136/esmoopen-2018-000377 |
| work_keys_str_mv | AT argilesguillem initialexperiencewiththebispecificanticeaanticd3antibodyanditsexpectedimpactonfuturetreatmentforpatientswithcolorectalcancer |